(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present? - 2This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- 3Flu cases skyrocket in US. See cases, where people got sick.
- 4Favored Chinese Dish: Make Your Determination
- 5France's Senate backs ban on social media platforms for under-15s
- Germany to create restitution council to return colonia-era acquired cultural artefacts
- The Green Transformation: 5 Feasible Living Practices
- Antivirus Programming for Exhaustive Security
- April’s full pink moon will rise in the night sky this week
- Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon
- An Excursion Through Renowned Western Network programs
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- German mid-sized firms gloomy on outlook, survey finds
